Nutzen verschiedener Verfahren zur Verbesserung der Spezifität von PSA in der Prostatakarzinomdiagnostik

Schambeck CM, Schmeller N, Stieber P, Jansen HM, Pahl H, Schneider W, Fateh-Moghadam A (1995) Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer. Urology 46: 195–199PubMedCrossRefGoogle Scholar

Semjonow A, Brandt B, Oberpenning F, Hertle L (1995) Unterschiedliche Bestimmungsverfahren erschweren die Interpretation des prostataspezifischen Antigens. Urologe A 34: 303–315PubMedGoogle Scholar

Carter HB, Pearson JD, Metter EJ et al (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease JAMA 267: 2215–2220PubMedCentralPubMedCrossRefGoogle Scholar

Riehmann M, Rhodes PR, Cook TD, Grose GS, Bruskewitz RC (1993) Analysis of variation in prostate-specific antigen values. Urology 42: 390–397PubMedCrossRefGoogle Scholar

Prestigiacomo AF, Stamey TA (1997) Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng/ml. range. J Urol 157: 189–194PubMedCrossRefGoogle Scholar

Schmid HP, McNeal JE, Stamey TA (1993) Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71: 2031–2040PubMedCrossRefGoogle Scholar

Schmid HP (1996) Prostate specific antigen doubling time in diagnosis and follow-up of patients with prostate cancer. Tumour Marker Update 8: 71–77Google Scholar

Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM (1993) Serum PSA in a community based population of healthy men. JAMA 270: 860–864PubMedCrossRefGoogle Scholar

Dalkin BL, Ahmann FR, Kopp JB (1993) PSA levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol 150: 1837–1839PubMedGoogle Scholar

Etzioni R, Shen Y, Petteway JC, Brawer MK (1996) Age-specific prostate-specific antigen: a reassessment. Prostate (Suppl) 7: 70–77PubMedCrossRefGoogle Scholar

Catalona WJ, Hudson MA, Scardino PT (1994) Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 2037–2042Google Scholar

Veneziano S, Pavlica P, Querz SR, Nanni G, Lalanne MG, Vecchi F (1990) Correlation between prostate-specific antigen and prostate volume evaluated by transrectal ultrasonography: usefulness in diagnosis of prostate cancer. Eur Urol 18: 112–116PubMedGoogle Scholar

Babaian RJ, Fritsche HA, Evans RB (1990) Prostate specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 4: 135–137PubMedCrossRefGoogle Scholar

Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH (1992) Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147: 815–816PubMedGoogle Scholar

Semjonow A, Hamm M, Rathert P, Hertle L (1994) Prostate-specific antigen corrected for prostate volume improves differentiation of benign prostatic hyperplasia and organ-confined prostatic cancer. Br J Urol 73: 538–543PubMedCrossRefGoogle Scholar

Wolff JM, Scholz A, Boeckmann W, Jakse G (1994) Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density. Eur Urol 25: 295–298PubMedGoogle Scholar

Brawer MK, Aramburu EAG, Chen GL, Preston SD, Ellis WJ (1993) The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 150: 369–373PubMedGoogle Scholar

Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O (1991) A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum ofpatients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222–226PubMedGoogle Scholar

Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lövgren T (1991) Prostate-specific antigen in serum occurs predominantly in complex with alpha-1-anti-chymotrypsin. Clin Chem 37/9: 1618–1625Google Scholar

Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J (1994) Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344: 1594–1598PubMedCrossRefGoogle Scholar

Luderer AA, Chen YT, Soriano TF et al. (1995) Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46: 187–194PubMedCrossRefGoogle Scholar

Froschermaier SE, Pilarsky CP, Wirth MP (1996) Clinical significance of the determination of noncomplexed prostate-specific antigen as a marker for prostate carcinoma. Urology 47: 525–528PubMedCrossRefGoogle Scholar

Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB (1995) Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214–1220PubMedCrossRefGoogle Scholar

Jung K, Lein M, Schnorr D, Henke W, Brux B, Loening S (1995) Prostataspezifisches Antigen (PSA) Einfluß des freien und gebundenen Anteils auf die klinische Aussagekraft als Tu-mormarker. Lab Med 19: 210–217Google Scholar

Semjonow A, Oberpenning F, Zechel C et al. (1995) The ratio of free to total prostate-specific antigen improves the differentiation of prostate cancer and benign prostatic hyper-plasia in highly selected men. Anticancer Research 15 [Suppl 6 A]: 2397Google Scholar

Catalona WJ, Partin AW, Slavin KM et al. (1997) A multicenter clinical trial evaluation of free PSA in the differentiation of prostate cancer from benign disease. J Urol A 157 [Suppl]: 434Google Scholar

Marley GM, Miller MC, Kattan MW et al. (1996) Free and complexed prostate specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyper-plasia. Urology 48: 16–22PubMedCrossRefGoogle Scholar

Reissigl A, Klocker H, Pointer J et al. (1996) Usefulness of the ratio free/total prostate specific antigen in addition to total PSA levels in prostate cancer screening. Urology 48: 62–66PubMedCrossRefGoogle Scholar

van Cangh PJ, de Nayer P, Sauvage P et al. (1996) Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate [Suppl] 7: 30–34PubMedGoogle Scholar

Woodrum D, French C, Shamel LB (1996) Stability of free prostate specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 48 [Suppl]: 33–39PubMedCrossRefGoogle Scholar

Mettlin C, Littrup PJ, Kane RA et al. (1994) Relative sensitivity and specificity ofserum prostate specific antigen (PSA) level compared with age-referenced PSA, PSA density, and PSA change. Cancer 74: 1615–1620PubMedCrossRefGoogle Scholar

Bangma CH, Kranse R, Blijenberg BG, Schröder FH (1995) The value of screening tests in the detection of prostate cancer. Part II. Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 46: 779–784PubMedCrossRefGoogle Scholar

Brawer MK (1996) Assessment of current methods of determing serum specific antigen levels in the early detection or screening for prostatic carcinoma. In: Cocket ATK, Khoury S, Asy Y, Chatelain C, Denis L, Griffiths K, Murphy G (eds) Proceedings of the 3rd International Consultation on BPH. Scientific Communication International, Paris, 1996, pp 371–381Google Scholar